View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Ageas: Upgrading net op. result FY26 target to >€1.5bn from €1.35bn in FY25 as M&A starts contributing / CFE: Strong 2H, flips to net cash and outlook better / Deceuninck: FY25 results in line with expectations, Türkiye a tad better / GBL: Exits Umicore fully / Vopak: Five-year SBB programme announced / Wolters Kluwer: 2025 roughly in line, good 2026 outlook

Kristof Samoy
  • Kristof Samoy

CFE FY25: In line results, solid debt reduction, margin strength in Co...

Over FY25, revenues equalled €1042m (-12% YoY) but EBIT up sharply at €44.9m (+40.3% YoY). The net result stood at €33.5m (LY: €24m). As such, the posted net result exceeds guidance calling for 2025 net profit close to the 2024 level. The company proposed a gross dividend of €0.50ps (€0.4PS LY). The consolidated order book stood at €1633m (vs. €1646m LY and €1650m per 9m25). Thanks to strong OCF of €64m, net debt turned into a net cash position of €43.8M (€41.7m net debt LY) . For 2026, CFE expe...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

CFE: Preview: underlying 2026 margin to improve / DEME: Preview: strong 2025, eyes on 2026 outlook / JDE Peet's: Acquisition by KDP expected to close in 2Q26 / Solvay: 2025 ends with strong FCF; 2026F und. EBITDA guidance slightly below, supported by one-off / UCB: Peer Moonlake investor day / Vastned: Beat on bottom line with operational metrics accelerating, but outlook remains weak

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

PostNL: 4Q25 notch better but supported by one-offs, Parcels below; outlook FY26 below. Recticel: FY25 preview

Stefano Toffano ... (+2)
  • Stefano Toffano
  • Wim Gille
Hilde Van Boxstael ... (+5)
  • Hilde Van Boxstael
  • Kristof Samoy
  • Michiel Declercq
  • Thibault Leneeuw
  • Wim Lewi
Thijs Berkelder
  • Thijs Berkelder
Guy Sips ... (+10)
  • Guy Sips
  • Jacob Mekhael
  • Kristof Samoy
  • Livio Luyten
  • Lynn Hautekeete
  • Michiel Declercq
  • Thibault Leneeuw
  • Thomas Couvreur
  • Wim Hoste
  • Wim Lewi

Dynamic Top Pick List Update February 2026: Removing ASMi; Adding UCB

After today's changes (ASMi out, UCB in), we maintain a balanced approach in our Dynamic Top Pick List, with a particular emphasis on value stocks that have been overlooked. Our defensive holdings are overweight, including real estate, which stands to benefit from lower interest rates. We remove ASMi from our Dynamic Top Pick List as the recent share price performance has driven the valuation meaningfully ahead of fundamentals. Since early December, FY27 diluted EPS expectations have risen by a...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Flow Traders: Preview 4Q25 / Kinepolis: January reassures with US box office revenue up 14% YoY, France visitors up 15% YoY / Lotus Bakeries: Peer Mondelez 4Q25 results / MICC: Peer Mondelez 4Q25 results / RELX / Wolters Kluwer: Anthropic moves into Legal / Signify: Analyst lunch highlights / TomTom: 4Q25 results, bridging a gap / UCB: Evenity sales exceeded US$2.1bn in FY25 as per Amgen

Guy Sips ... (+5)
  • Guy Sips
  • Jacob Mekhael
  • Mathijs Geerts Danau
  • Wim Hoste
  • Wim Lewi
Jacob Mekhael
  • Jacob Mekhael

UCB Presents supportive three-year Bimzelx data in HS at EHSF

UCB announced that three-year data from the BE HEARD trials for Bimzelx in moderate to severe HS will be presented at the Conference of the European Hidradenitis Suppurativa Foundation EHSF, being held 4–6 February in Malta. The data show high rates of total HS resolution at 3 years, high rates of improvement from moderate or severe HS to mild disease, as well as strong draining tunnel resolution. This continues to highlight Bimzelx' benefit in this patient group, which we believe will further d...

Guy Sips ... (+4)
  • Guy Sips
  • Jacob Mekhael
  • Wim Hoste
  • Wim Lewi
Jacob Mekhael
  • Jacob Mekhael

UCB Model update ahead of FY25 results

Following the second guidance upgrade for FY25 (announced 5 December 2025), we update our UCB model ahead of FY25 results. UCB now expects revenue to exceed €7.6bn, representing +24% y/y (previously at least €7bn). The upgraded guidance reflects - next to the continued growth of Rystiggo, Zilbrysq, Fintepla and Evenity – strong performance of Bimzelx, including a strong momentum in hidradenitis suppurativa (HS) and a favourable payer mix in the US. Our model update increases Bimzelx FY25 sales t...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch